Recognition and management of antibodies to human platelet antigens in platelet transfusion-refractory patients

Immunohematology

Volumn 25, Issue 3, 2009, Pages 119-124

  Vassallo, Ralph R ^a  

^a AMERICAN RED CROSS BLOOD SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HLA ANTIBODY; THROMBOCYTE ANTIGEN;

ALLOIMMUNIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC SUSCEPTIBILITY; HUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE TRANSFUSION;

ANTIGENS, HUMAN PLATELET; BLOOD PLATELETS; HUMANS; ISOANTIBODIES; PLATELET TRANSFUSION; PLATELETPHERESIS;

EID: 77649096232     PISSN: 0894203X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Vassallo RR Jr. New paradigms in the management of alloimmune refractoriness to platelet transfusions. Curr Opin Hematol 2007;14:655-63.
2. Seftel MD, Growe GH, Petraszko T, et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004;103:333-9.
3. Kerkhoffs JL, Eikenboom JC, van de Watering LM, et al. The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion 2008;48:1959-65.
4. Doughty HA, Murphy MF, Metcalfe P, et al. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994;66:200-5.
5. Slichter SJ, Davis K, Enright H, et al. Factors affecting posttranfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106-14.
6. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008;142:348-60.
7. Daly PA, Schiffer CA, Aisner J, Wiernik PH. Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA 1980;243:435-8.
8. Yankee RA, Grumet FC, Rogentine GN. Platelet transfusion: the selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. N Engl J Med 1969;281:1208-12.
9. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med i997;337:1861-9.
10. AuBuchon JP, Leach MF. Investigating the possibility of drug-dependent platelet antibodies. Immunohematology 2009;25:136-140.
11. Cooling L. ABO and platelet transfusion therapy. Immunohematology 2007;23:20-33.
12. [No authors listed.] Detection of platelet-reactive antibodies in patients who are refractory to platelet transfusions, and the selection of compatible donors. Vox Sang 2003;84:73-88.
13. Heal JM, Blumberg N, Masel D. An evaluation of cross-matching, HLA and ABO matching for platelet transfusions to refractory patients. Blood 1987;60:23-30.
14. Petz LD. The HLA system and platelet transfusion. In: Murphy S, ed. The HLA system: basic biology and clinical applications. Bethesda, MD: American Association of Blood Banks, 1999.
15. Curtis BR, McFarland JG. Detection and identification of platelet antibodies and antigens in the clinical laboratory. Immunohematology 2009;25:125-135.
16. Semana G, Zazoun T, Alizahed M, et al. Genetic susceptibility and anti-human platelet antigen 5b alloimmunization: role of class II and TAP genes. Hum Immunol 1996;46:114-19.
17. A1 platelet antigen: results of a prospective study. Br J Haematol 1990;74:209-15.
18. Norton A, Allen DL, Murphy MF. Review: platelet alloantigens and antibodies and their clinical significance. Immunohematology 2004;20:89-102.
19. Curtis BR, Ali S, Glazier AM, et al. Isoimmunization against CD36 (glycoprotein IV): description of four cases of neonatal alloimmune thrombocytopenia and brief review of the literature. Transfusion 2002;42:1173-9.
20. Taaning E, Sinonsen AC, Hjelms E, et al. Platelet alloimmunization after transfusion. Vox Sang 1997;72:238-41.
21. Kiefel V, Konig C, Kroll H, Santoso S. Platelet alloantibodies in transfused patients. Transfusion 2001;41:766-70.
22. Kickler T, Kennedy SD, Braine HG. Alloimmunization to platelet-specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients. Transfusion 1990;30:622-5.
23. Legier TJ, Fischer I, Dittmann J, et al. Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol 199;74:185-9.
24. Kurz M, Greinix H, Hocker P, et al. Specificities of anti-platelet antibodies in multitransfused patients with haemato-oncological disorders. Br J Haematol 1996;95:564-9.
25. Godeau B, Fromont P, Seror T, et al. Platelet alloimmunization after multiple transfusions: a prospective study of 50 patients. Br J Haematol 1992;81:395-400.
26. Uhrynowska M, Zupanska B. Platelet-specific antibodies in transfused patients. Eur J Haematol 1996;56:248-51.
27. McGrath K, Wolf M, Bishop J, et al. Transient platelet and HLA antibody formation in multitransfused patients with malignancy. Br J Haematol 1988;68:345-50.
28. Murphy MF, Metcalfe P, Ord J, et al. Disappearance of HLA and platelet-specific antibodies in acute leukaemia patients alloimmunized by multiple transfusions. Br J Haematol 1987;67:255-60.
29. McFarland JG. Alloimmunization and platelet transfusion. Semin Hematol 1996;33:315-28.
30. Schnaidt M, Northoff H, Wernet D. Frequency and specificity of platelet-specific alloantibodies in HLA-immunized haematologic-oncologic patients. Transfus Med 1996;6:111-14.
31. Sanz C, Freire C, Alcorta I, et al. Platelet-specific antibodies in HLA-immunized patients receiving chronic platelet support. Transfusion 2001;41:762-5.
32. A1) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions. Transfusion 2001;41:984-7.
33. a antibody alone. Vox Sang 2001;81:42-4.
34. Lo SC, Chang JS, Lin SW, Lin DT. Platelet alloimmunization after long-term red cell transfusion in transfusion-dependent thalassemia patients. Transfusion 2005;45:761-5.
35. Ertel K, Al-Tawil M, Santoso S, Kroll H. Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes. Transfusion 2005;45:366-73.
36. Berry JE, Murphy CM, Smith GA, et al. Detection of Gov system antibodies by MAIPA reveals an immunogenicity similar to the HPA-5 alloantigens. Br J Haematol 2000;110:735-42.
37. Semple JW, Speck ER, Milev YP, et al. Indirect allorecognition of platelet by T helper cells during platelet transfusions correlates with anti-major histocompatibility complex antibody and cytotoxic T lymphocyte formation. Blood 1995;86:805-12.
38. Sayeh E, Aslam R, Speck ER, et al. Immune responsiveness against allogeneic platelet transfusions is determined by the recipient's major histocompatibility complex class II phenotype. Transfusion 2004;44:1572-8.
39. Lucas GF, Rogers SE. Evaluation of an enzyme-linked immunosorbent assay kit (GTi PakPlus) for the detection of antibodies against human platelet antigens. Transfus Med 1999;9:63-7.
40. Allen D, Ouwehand WH, de Haas M, et al. Interlaboratory variation in the detection of HPA-specific alloantibodies and in molecular HPA typing. Vox Sang 2007;93:316-24.
41. Lucas GF, Metcalfe P. Platelet and granulocyte glycoprotein polymorphisms. Transfus Med 2000;10:157-74.
42. Cserti-Gazdewich CM, Dzik WH, Dorn ME, et al. Quantitation of CD36 (platelet glycoprotein IV) expression on platelets and monocytes by flow cytometry: application to the study of Plasmodium falciparum malaria. Cytometry B Clin Cytom 2009;76:127-34.